123 related articles for article (PubMed ID: 9554255)
1. Will adjuvants be needed for vaccines of the future?
Bomford R
Dev Biol Stand; 1998; 92():13-7. PubMed ID: 9554255
[TBL] [Abstract][Full Text] [Related]
2. Adjuvants and delivery systems for viral vaccines--mechanisms and potential.
Jennings R; Simms JR; Heath AW
Dev Biol Stand; 1998; 92():19-28. PubMed ID: 9554256
[TBL] [Abstract][Full Text] [Related]
3. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
Wong CP; Okada CY; Levy R
J Immunol; 1999 Feb; 162(4):2251-8. PubMed ID: 9973501
[TBL] [Abstract][Full Text] [Related]
4. [C3d molecular adjuvant increases the immunity of human chorionic gonadotropin beta DNA contraceptive vaccination and changes its immune response from Th1 to Th2].
Zhao XR; Li DJ; Yuan MM; Cai LR; Sun XX
Zhonghua Yi Xue Za Zhi; 2003 Nov; 83(21):1906-9. PubMed ID: 14642077
[TBL] [Abstract][Full Text] [Related]
5. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccination: antigen presentation and the induction of immunity.
Shedlock DJ; Weiner DB
J Leukoc Biol; 2000 Dec; 68(6):793-806. PubMed ID: 11129646
[TBL] [Abstract][Full Text] [Related]
7. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
8. Adjuvants in perspective.
Vogel FR
Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
[TBL] [Abstract][Full Text] [Related]
9. Immunological adjuvants and their modes of action.
Allison AC
Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):141-7. PubMed ID: 9597079
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant activities of saponins from traditional Chinese medicinal herbs.
Song X; Hu S
Vaccine; 2009 Aug; 27(36):4883-90. PubMed ID: 19559122
[TBL] [Abstract][Full Text] [Related]
11. The search for novel adjuvants for early life vaccinations: can "danger" motifs show us the way?
Kovarik J; Siegrist CA
Arch Immunol Ther Exp (Warsz); 2001; 49(3):209-15. PubMed ID: 11478395
[TBL] [Abstract][Full Text] [Related]
12. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
13. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
[TBL] [Abstract][Full Text] [Related]
14. Induction and direction of immune responses by vaccine adjuvants.
Schijns VE
Crit Rev Immunol; 2001; 21(1-3):75-85. PubMed ID: 11642615
[TBL] [Abstract][Full Text] [Related]
15. Adjuvants for vaccines, a quest.
Audibert F
Int Immunopharmacol; 2003 Aug; 3(8):1187-93. PubMed ID: 12860174
[TBL] [Abstract][Full Text] [Related]
16. Vaccine adjuvant technology: from theoretical mechanisms to practical approaches.
Schijns VE; Tangerås A
Dev Biol (Basel); 2005; 121():127-34. PubMed ID: 15962475
[TBL] [Abstract][Full Text] [Related]
17. Advances in saponin-based adjuvants.
Sun HX; Xie Y; Ye YP
Vaccine; 2009 Mar; 27(12):1787-96. PubMed ID: 19208455
[TBL] [Abstract][Full Text] [Related]
18. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
19. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants.
Sokolovska A; Hem SL; HogenEsch H
Vaccine; 2007 Jun; 25(23):4575-85. PubMed ID: 17485153
[TBL] [Abstract][Full Text] [Related]
20. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.
Chow YH; Chiang BL; Lee YL; Chi WK; Lin WC; Chen YT; Tao MH
J Immunol; 1998 Feb; 160(3):1320-9. PubMed ID: 9570550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
